A new round of health care negotiations has come to adjust the direction of the forecast.

On August 20th, the National Health Insurance Administration issued two announcements, the Work Programme for the Adjustment of the National Health Insurance Drug Catalog in 2020 and the Guidelines for the Adjustment and Declaration of the National Health Insurance Drug Catalog in 2020, marking the official opening of the negotiations on the National Health Insurance Drug in 2020.
In order to reduce the burden on patients, through negotiations, so that drug prices down and then paid by health insurance, this way of volume-for-price than the previous simple administrative price reduction, has indeed been well received by all parties, and achieved significant results, from 2016 onwards, held once a year, has been held four consecutive negotiations.
This paper will be from the success rate, the proportion of Chinese and foreign varieties, price reduction and beneficiary enterprises and other four aspects, the first four countries to do a comprehensive comparative analysis, in response to the upcoming 2020 state talks to provide reference.
, the success rate of the first national talks in 2016 was led by the former National Health planning commission, a total of 5 varieties to participate, the final success of 3, the success rate of 60%.
2017 to coincide with the adjustment of the health insurance catalog, the higher price of 44 drugs out to focus negotiations, the final 36 success, the success rate increased to 82%.
May 1, 2018 imports of anti-cancer drugs to implement zero tariffs, the Prime Minister for the "I am not a drug god" issued instructions, in the context of this greatly improved access to drugs, especially anti-cancer drugs, on October 10 of that year, a total of 18 anti-cancer drugs to participate in the negotiations, the final 17 success, success rate reached an unprecedented 94.4%.
still in line with the adjustment of the large catalogue, more varieties will be included in the national talks in 2019, a total of 119 varieties to participate in the negotiations, the final 70 success, the success rate of 58.8% (Figure 1). the success rate of the
-nation talks has been increasing because the successful varieties of negotiations have indeed achieved a substantial increase in sales volume, enterprises have benefited, enterprises from wait-and-see to active participation - it is estimated that in 2020 the participation of state-to-state talks enterprises will be higher, the success rate will be high.
Take AstraZenein's fluvy group, which successfully negotiated in the second batch in 2017, as a result of the gradual landing of the state-to-state varieties in the second half of the year, its overall sales growth rate in 2017 was only 70%, but the growth rate in the fourth quarter of 2017 increased sharply, reaching 121%, and the growth rate in the first and second quarters of 2018 was as high as 182% and 210%, and enterprises achieved a price-for-price effect through health insurance negotiations (Figure 2).
2, the Sino-foreign proportion of medical insurance negotiations for patients to reduce the burden, but also to encourage pharmaceutical innovation, and China's pharmaceutical innovation is just beginning, so in previous national talks, imported varieties into a lot.
in its first national talks in 2016, in addition to Ektini hydrochloride (Kemena) from Beda Pharmaceuticals, fumaic acid for nofovdiure (Vered, GSK) and Gificini (Ilysa, AZ) Are imported, in 2017 the successful negotiations of 36 varieties, 17 domestic, 19 foreign enterprises, domestic accounted for 47%, in 2018 the special anti-cancer drug talks successful 17 of the only 2 seats, only 12%.
In recent years, the domestic set off the climax of pharmaceutical innovation, but also achieved obvious results, many local pharmaceutical companies have been approved for new drugs, so in the fourth national talks in 2019, domestic drugs performed well; 3 (of which 8 belong to major national special projects), 37 imports, the proportion of domestic production as high as 47%;
the environment for domestic pharmaceutical innovation is improving day by day, and the results of pharmaceutical innovation are making rapid progress, so the upcoming 2020 state talks will have more successful negotiations on new domestic drugs.
, one of the main purposes of the price reduction negotiations is to bring down the price, so the price reduction of each negotiation has become the most intuitive measure of the outcome of the negotiations.
's first state talk in 2016 brought drug prices down by nearly two-thirds (an average of 59 per cent), and invisibly set a benchmark for subsequent declines in negotiations, with subsequent declines largely fluctuating around this decline; 44% in 17 years and 56.7% in 2018, with an average decline of 60.7% in 2019 for the 70 new negotiated varieties, almost the same as in 2016 (Figure 4).
it remains to be seen whether this year's drop in state talks will be around 60 per cent.
4, who is the winner to 2019 for example, the local enterprises a total of 22 enterprises 24 varieties of successful negotiations, including Hengrui's Maly acid pyridine tablets, thioperan injections, meth sulfonate apatini tablets and other 3 varieties of success, become the biggest winner of local enterprises.
The most beneficial foreign company in the 2019 talks was Novarro, with nine varieties successfully negotiated, seven of which were new and two were successful renewals, followed by Roche's eight (including three renewals), Johnson and Johnson's seven, Gilead's six (including two renewals) and AZ5 (including one renewal) (Figure 5).
The upcoming 2020 national health-care drug negotiations, which cover a wider range of new and cost-effective drugs into the health-care catalogue, will indeed improve drug access, encourage innovation and significantly reduce the financial burden on patients.
.